News

Shire has announced that the FDA has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire for the treatment

A growing menace of pseudo prescription drugs in Europe’s traditional supply chain is very alarming. In order to tackle this, Siemens and EFPIA (European Federation of Pharmaceutical Industries

Impax Pharmaceuticals (Impax) has initiated a multinational phase III trial of its late-stage drug candidate IPX066 in advanced parkinson’s disease (PD) patients. IPX066 is an investigational extended release

Arena has reported that data from the pivotal BLOOM phase 3 trial demonstrate lorcaserin increased excess weight loss, improved markers of cardiovascular risk and glycemic parameters, and was

Orexigen has announced a new data from the COR-I, COR-II and COR-Diabetes trials for Contrave (bupropion SR/ naltrexone SR) to expand on top-line results announced in July. Contrave

Hovione has acquired an aseptic spray-drying production line, vial filling and back up utilities from Acusphere, a company located in Boston. The equipment includes sterile filtration, aseptic spray

GEA Niro has extended its offerings to include contract manufacturing on extensive cGMP spray drying facilities. The GEA Niro Pharma Test Station is available for developing spray drying

Abbott has opened a new Nutrition facility at the Research Park on the University of Illinois campus. The company will use the facility to research and develop nutritional

Exelixis and Bristol-Myers Squibb have reported updated phase 2 clinical data, which demonstrates XL184 activity in patients with glioblastoma multiforme (GBM). XL184 (BMS-907351) is an investigational oral inhibitor